All In Biotech

Drug Trial Radar · NCT06639087

A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

8

Actual

Start

Sep 27, 2024

Primary completion

May 29, 2025

Study completion May 29, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to investigate the effects and safety of AZD5462 on top of dapagliflozin in participants with heart failure and moderate renal impairment.

Conditions

  • Renal Impairment
  • Heart Failure

Interventions

  • AZD5462Drug

    Participants will receive AZD5462 on top of dapagliflozin once daily.

  • DapagliflozinDrug

    Participants will receive dapagliflozin once daily with AZD5462 or placebo.

  • PlaceboOther

    Participants will receive placebo on top of dapagliflozin once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in sodium excretionTime frame: From Baseline to Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Sofia, Bulgaria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.